A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

ClinicalTrials.gov ID: NCT07325526

Public ClinicalTrials.gov record NCT07325526. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 5, 2026, 12:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIa Double-blind, Placebo-controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 3802876 in Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is open to adults with a type of confirmed liver condition called compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH). The purpose of this study is to find out how well a study medicine called BI 3802876 is tolerated in people with this condition. The study looks at how different doses of BI 3802876 are handled by the body. BI 3802876 is being developed to improve liver health in people living with this liver condition. Participants are put in 3 different dose groups randomly, which means by chance. Participants within a group get BI 3802876 or placebo. Placebo looks like BI 3802876 but does not contain any medicine. Participants have more than twice the chance of receiving BI 3802876 than placebo. The study medicine is given as an infusion into a vein. Participants are in the study for about half a year. During this time, they visit the study site 12 times. At 2 visits, participants get the study medicine. Doctors collect information on any health problems and take blood samples to check how BI 3802876 is handled by the body. They compare results between the groups.

Study identification

NCT ID: NCT07325526
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Boehringer Ingelheim; Industry
Enrollment: 30 participants

Conditions and interventions

Conditions

Liver Cirrhosis

Interventions

BI 3802876 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 26, 2026
Primary completion: Aug 4, 2027
Completion: Aug 4, 2027
Last update posted: Aug 31, 2026

2026 – 2027

United States locations

U.S. sites: 26
U.S. states: 14
U.S. cities: 24

Facility	City	State	ZIP	Site status
Arizona Clinical Trials - Chandler	Chandler	Arizona	85225	Not yet recruiting
Southern California Research Center	Coronado	California	92118	Recruiting
Velocity Clinical Research, San Diego	La Mesa	California	91942	Not yet recruiting
Kaiser Permanente - Los Angeles Medical Center	Los Angeles	California	90027	Not yet recruiting
Catalina Research Institute, LLC	Montclair	California	91763	Recruiting
Peak Gastroenterology Associates	Colorado Springs	Colorado	80907	Recruiting
Schiff Center Liver Diseases	Miami	Florida	33136	Not yet recruiting
Panax Clinical Research	Miami Lakes	Florida	33014	Recruiting
Covenant Metabolic Specialists, LLC - University Park	University Park	Florida	34201	Recruiting
Centricity Research Columbus Georgia Multispecialty	Columbus	Georgia	31904	Recruiting
University of Iowa Hospitals and Clinics	Iowa City	Iowa	52242	Not yet recruiting
University of Kansas Medical Center	Kansas City	Kansas	66160	Not yet recruiting
Johns Hopkins Hospital	Baltimore	Maryland	21287	Not yet recruiting
Mayo Clinic, Rochester	Rochester	Minnesota	55905	Not yet recruiting
Columbia University Medical Center	New York	New York	10032	Not yet recruiting
Lucas Research, Inc.	Morehead City	North Carolina	28557	Recruiting
Medical University of South Carolina	Charleston	South Carolina	29425	Recruiting
Nashville General Hospital	Nashville	Tennessee	37209	Recruiting
Texas Clinical Research Institute, LLC	Arlington	Texas	76012	Not yet recruiting
Epic Medical Research - Carrollton	Carrollton	Texas	75006	Recruiting
The Liver Institute at Methodist Dallas	Dallas	Texas	75203	Not yet recruiting
Baylor Scott & White Research Institute	Dallas	Texas	75246	Not yet recruiting
Epic Medical Research - Fort Worth	Fort Worth	Texas	76120	Recruiting
Houston Methodist Hospital	Houston	Texas	77030	Not yet recruiting
Pioneer Research Solutions, Inc.	Houston	Texas	77099	Recruiting
American Research Corporation at the Texas Liver Institute	San Antonio	Texas	78215	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07325526, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 31, 2026 · Synced Sep 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07325526 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →